Anti-Müllerian hormone type II receptor (AMHR2)

Anti-Müllerian hormone type II receptor (AMHR2) is a serine/threonine kinase receptor and a member of the TGF-β type II receptor family, dedicated specifically to binding anti-Müllerian hormone (AMH)[1][2][3][5]. It plays a central role in reproductive development, mediating regression of the Müllerian ducts in male embryos and regulating ovarian folliculogenesis in females[1][2][3][5]. Structurally, AMHR2 features a unique extended finger 1 loop, distinguishing its ligand-binding properties from other TGF-β type II receptors and enabling high specificity for AMH[1][3][5]. Upon AMH binding, AMHR2 forms a signaling complex with type I receptors, ultimately triggering SMAD signaling cascades that regulate gene expression involved in sexual differentiation and reproductive function[2][3][5]. Genetic disruption of AMHR2 causes persistent Müllerian duct syndrome (PMDS) and can be implicated in various disorders of sexual development[1][2][5]. No clinically approved drugs directly targeting AMHR2 currently exist, but understanding its unique structure and interaction mechanisms is fueling preclinical exploration of antibody and peptide modulators[3][5].

Other names

Müllerian inhibiting substance type II receptorMIS type II receptorAMH receptor type IIAMHR2

Ligand (AMH) binding triggers heterotetrameric complex formation with type I receptors, activating SMAD-dependent transcriptional pathways[2][3][5].